Research of Intensive Lifestyle Intervention for PCOS Patients With IGT
Primary Purpose
Polycystic Ovary Syndrome
Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
intensive lifestyle intervention
GLP-1 Receptor Agonists
Metformin
Acarbose
Sponsored by
About this trial
This is an interventional treatment trial for Polycystic Ovary Syndrome focused on measuring PCOS, intensive lifestyle intervention, IGT, drugs treatment
Eligibility Criteria
Inclusion Criteria:
- Overweight and obese PCOS patients with newly diagnosed IGT; PCOS diagnosis based on 1990 NIH criteria. Overweight / obesity diagnostic criteria according to WHO-WPR. IGT diagnostic criteria according to 1998 WHO diagnostic criteria.
Exclusion Criteria:
- Except for serious complications (cardiovascular events and recent significant kidney or lung disease within 3 months), and had high blood pressure (>160/100mmHg), blood sugar and high blood lipids (glycated hemoglobin> 11%, triglycerides >600 mg/dl).
Sites / Locations
- Renji Hospital Department of Endocrinology and Metabolism
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Experimental
Arm Label
intensive lifestyle intervention
GLP-1 Receptor Agonists
metformin
acarbose
Arm Description
3 months intensive lifestyle intervention, including low GI diet and exercise.
3 months GLP-1 Receptor Agonists treatment
3 months metformin treatment
3 months acarbose treatment
Outcomes
Primary Outcome Measures
changes of Islet β-cell functions from baseline
Insulin and blood glucose levels
Secondary Outcome Measures
Incretin
GLP-1, glucagon,GIP, PYY
Intra-abdominal fat distribution
measured by MRI
Sex Hormone
testosterone, estradiol, LH, and FSH
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02446834
Brief Title
Research of Intensive Lifestyle Intervention for PCOS Patients With IGT
Official Title
Research of Intensive Lifestyle Intervention for Overweight PCOS Patients With Impaired Glucose Tolerance in Their Metabolic and Reproductive Abnormalities Treatment
Study Type
Interventional
2. Study Status
Record Verification Date
November 2017
Overall Recruitment Status
Completed
Study Start Date
April 2015 (Actual)
Primary Completion Date
December 2017 (Actual)
Study Completion Date
April 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
RenJi Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Compare the efficacy between intensive lifestyle intervention and drugs (GLP-1 Receptor Agonists, metformin and acarbose) for PCOS patients with early onset diabetes in their metabolic and reproductive abnormalities treatment; clear the treatment effect and mechanism of intensive lifestyle intervention to PCOS.
Detailed Description
We designed a non randomized control study to compare the efficacy between intensive lifestyle intervention and drugs (GLP-1 Receptor Agonists, metformin and acarbose) for PCOS patients with early onset diabetes in their metabolic and reproductive abnormalities treatment We planed to enroll 48 patients.Overweight and obese PCOS patients with newly diagnosed IGT; PCOS diagnosis based on 1990 NIH criteria. Overweight / obesity diagnostic criteria according to WHO-WPR. IGT diagnostic criteria according to 1998 WHO diagnostic criteria. Except for serious complications (cardiovascular events and recent significant kidney or lung disease within 3 months), and had high blood pressure (>160/100mmHg), blood sugar and high blood lipids (glycated hemoglobin> 11%, triglycerides >600 mg/dl).
Then we devided the 48 patients into 4 groups: intensive lifestyle intervention group, GLP-1 group, metformin group and acarbose group, and each group 12 samples. Each group use specific treatment(showed as the group name) 3 months. Before and after the intervention, the blood samples would be collected to Glucose, Insulin, GLP-1, Glucagon, sex hormones, Blood chemistry for liver and kidney function ect, as well as the image examinations.
We will compare the data of each patient, finally identify the treatment effect and mechanism of intensive lifestyle intervention to PCOS.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Polycystic Ovary Syndrome
Keywords
PCOS, intensive lifestyle intervention, IGT, drugs treatment
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Masking Description
Open Label
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
intensive lifestyle intervention
Arm Type
Experimental
Arm Description
3 months intensive lifestyle intervention, including low GI diet and exercise.
Arm Title
GLP-1 Receptor Agonists
Arm Type
Experimental
Arm Description
3 months GLP-1 Receptor Agonists treatment
Arm Title
metformin
Arm Type
Experimental
Arm Description
3 months metformin treatment
Arm Title
acarbose
Arm Type
Experimental
Arm Description
3 months acarbose treatment
Intervention Type
Behavioral
Intervention Name(s)
intensive lifestyle intervention
Other Intervention Name(s)
group 1
Intervention Description
3 months low GI diet and exercise
Intervention Type
Drug
Intervention Name(s)
GLP-1 Receptor Agonists
Other Intervention Name(s)
group 2
Intervention Description
Use GLP-1 Receptor Agonists 3 months to treat PCOS
Intervention Type
Drug
Intervention Name(s)
Metformin
Other Intervention Name(s)
group 3
Intervention Description
Use metformin 3 months to treat PCOS
Intervention Type
Drug
Intervention Name(s)
Acarbose
Other Intervention Name(s)
group 4
Intervention Description
Use acarbose 3 months to treat PCOS
Primary Outcome Measure Information:
Title
changes of Islet β-cell functions from baseline
Description
Insulin and blood glucose levels
Time Frame
up to 12 weeks
Secondary Outcome Measure Information:
Title
Incretin
Description
GLP-1, glucagon,GIP, PYY
Time Frame
up to 12 weeks
Title
Intra-abdominal fat distribution
Description
measured by MRI
Time Frame
up to 12 weeks
Title
Sex Hormone
Description
testosterone, estradiol, LH, and FSH
Time Frame
up to 12 weeks
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
14 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Overweight and obese PCOS patients with newly diagnosed IGT; PCOS diagnosis based on 1990 NIH criteria. Overweight / obesity diagnostic criteria according to WHO-WPR. IGT diagnostic criteria according to 1998 WHO diagnostic criteria.
Exclusion Criteria:
Except for serious complications (cardiovascular events and recent significant kidney or lung disease within 3 months), and had high blood pressure (>160/100mmHg), blood sugar and high blood lipids (glycated hemoglobin> 11%, triglycerides >600 mg/dl).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tao Tao, MD
Organizational Affiliation
RenJi Hospital Department of Endocrinology and Metabolism
Official's Role
Study Chair
Facility Information:
Facility Name
Renji Hospital Department of Endocrinology and Metabolism
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200127
Country
China
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Research of Intensive Lifestyle Intervention for PCOS Patients With IGT
We'll reach out to this number within 24 hrs